Harrow, Inc. (HROW) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, operating through two primary segments: Branded (FDA-approved pharmaceutical products) and ImprimisRx (ophthalmology-focused compounding business). The company is currently an accelerated filer.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $63.74 million | $48.94 million | $111.57 million | $83.53 million |
| Gross Profit | $47.51 million | $36.40 million | $79.82 million | $60.43 million |
| Gross Margin | 74.5% | 74.4% | 71.5% | 72.4% |
| Net Income (Loss) | $4.99 million | $(6.47) million | $(12.79) million | $(20.04) million |
| Diluted EPS | $0.13 | $(0.18) | $(0.35) | $(0.56) |
| Cash and Equivalents | $52.96 million | (Balance Sheet: Dec 31, 2024: $47.25 million) | ||
| Total Debt (Principal) | $226.51 million | (Includes $107.5M Oaktree Loan & $75M 2026 Notes) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 30.2% year-over-year for Q2 2025, driven primarily by significant growth in the Branded segment. VEVYE revenue surged to $18.64 million (up $14.33 million) and IHEEZO revenue rose to $18.34 million (up $7.04 million).
- Profitability: The company returned to profitability in Q2 2025 with net income of $4.99 million, compared to a net loss of $6.47 million in Q2 2024. However, the company remains unprofitable on a year-to-date basis.
- Debt Restructuring: A significant portion of debt has been reclassified as current. The Oaktree Loan ($107.5M) and 2026 Notes ($75M) are now due within 12 months (Jan 2026 and Apr 2026, respectively), increasing current liabilities to $248.9 million.
- Operating Expenses: SG&A expenses increased to $33.2 million in Q2 2025 from $31.8 million in Q2 2024, largely due to hiring for sales and marketing, partially offset by a decrease in stock-based compensation.
Outlook, Risks, and Management Commentary
- Liquidity and Refinancing Risk: Management highlights a substantial liquidity risk. The Oaktree Loan and 2026 Notes mature in early 2026. While management believes refinancing is probable based on collateral strength and cash flows, there is no assurance. Failure to refinance or sell assets could raise substantial doubt about the company's ability to continue as a going concern.
- Strategic Initiatives:
- Project Beagle: A 360-degree review to transition ImprimisRx patients from compounded formulations to Harrow-owned FDA-approved products. The company discontinued compounding Klarity-C and Klarity PF on June 30, 2025.
- New Agreements: Entered into a commercialization agreement with Samsung Bioepis for BYOOVIZ and OPUVIZ (July 2025) and acquired exclusive U.S. rights to BYQLOVI from Formosa Pharmaceuticals (June 2025).
- Legal Proceedings: In November 2024, a jury awarded Harrow $34.9 million in a lawsuit against Ocular Science, Inc. (OSRX). Due to uncertainty regarding collection, this amount has not been recognized in the financial statements.
- Regulatory Risks: The company faces ongoing scrutiny from the FDA regarding its New Jersey outsourcing facility (NJOF) and compounding practices, including recent Form 483 observations and discussions regarding quality systems.
Investor Verification Checklist
- Refinancing Status: Verify the progress of discussions with Oaktree and other lenders regarding the $182.5 million in debt maturing in 2026.
- Collection of Legal Award: Monitor developments regarding the $34.9 million verdict against OSRX to assess the probability of collection and potential future recognition.
- Product Transition Impact: Assess the financial impact of "Project Beagle" on the ImprimisRx segment as patients transition from compounded products to branded alternatives.
- Regulatory Compliance: Review any new FDA correspondence or enforcement actions related to the NJOF facility and compounding operations.
- Cash Burn vs. Generation: Analyze the sustainability of operating cash flows ($18.9M YTD 2025) against the upcoming debt service obligations and potential refinancing costs.